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HLA mismatching is an important risk factor for antibody-mediated rejection and transplant
failure.With the realization HLA antibodies recognize epitopes rather than antigens, it has
becomeapparentthatdonor-recipientcompatibilityshouldbeassessedattheepitopelevel.
Recent developments have increased our understanding of the structural basis of HLA anti-
genicity, i.e., the reactivity with speciﬁc antibody and, immunogenicity, i.e., the ability to
induce an antibody response. HLAMatchmaker is a computer algorithm that considers
each HLA antigen as a series of small conﬁgurations of polymorphic residues referred to
as eplets as essential components of HLA epitopes.This article addresses the relevance
of determining epitope-speciﬁcities of HLA antibodies in the identiﬁcation of acceptable
mismatches for sensitized patients considered for transplantation. Permissible mismatch-
ing for non-sensitized patients aimed to prevent or reduce HLA antibody responses could
consider epitope loads of mismatched antigens and the recently developed non-self–self
paradigm of epitope immunogenicity.
Keywords: HLA antibody, HLA epitope, HLAMatchmaker, eplet, non-self–self paradigm of HLA epitope
immunogenicity
INTRODUCTION
HLAantibodiesplayanimportantroleintransplantrejectionand
failure and they result after exposure to mismatched HLA anti-
gens which can occur after transplantation as well as following
blood transfusions or during pregnancy. Traditionally, antibodies
have been described as speciﬁc for HLA antigens such as anti-A1,
anti-B7, and anti-DR1, or for serologically cross-reacting HLA
antigens such as the A2-CREG and the B7-CREG. It has now
becomeapparentthatHLAantigenscarrymultipleepitopeswhich
can be deﬁned by molecular structural modeling and amino acid
sequence differences between alleles. HLAMatchmaker represents
an epitope-based approach to assess HLA compatibility and to
select suitable donors for patients in need of an organ trans-
plant (Duquesnoy,2002,2006). Three recent reviews describe the
concept of HLAMatchmaker and its usefulness in HLA epitope
matching for organ transplantation (Duquesnoy, 2008a, 2011a;
Duquesnoy and Marrari, 2009).
Brieﬂy, HLAMatchmaker considers each HLA antigen as a
stringofaminoacidconﬁgurationsaskeyelementsofepitopesthat
canelicitspeciﬁcalloantibodies.Theoriginalversionusedtriplets,
i.e.,linear sequences of three residues (Duquesnoy,2002),but the
so-calledepletversionisbasedonstereochemicalmodelingofpro-
tein antigen–antibody complexes and the contributions of critical
amino acid residues that dominate in antigen–antibody binding
(Duquesnoy, 2006). The residues of such patches are within a
threeÅngstromradiusof anon-self residue.Eachepletisassigned
a position number in the amino acid sequence and the notation
system lists only polymorphic residues marked with the standard
lettercode.HLAMatchmakerprogramsconsiderClassI(Duques-
noy, 2006), Class II (Duquesnoy and Askar, 2007), and MICA
compatibilityandantibodyanalysis(Duquesnoyetal.,2008a).The
www.HLAMatchmaker.netwebsiteisaninformationresourceand
has Excel based analysis programs that can be downloaded free of
charge.
HLA EPITOPE ANTIGENICITY
Recent developments have increased our understanding of the
structural basis of HLA antigenicity, i.e., reactivity with speciﬁc
antibody. HLA antibodies are speciﬁc for epitopes that can be
deﬁned by single eplets or pairs consisting of a non-self eplet pre-
sented by the immunizing antigen and a self eplet shared by the
antibody producer and the immunizer (Duquesnoy et al., 2005;
Marrari et al., 2010).
The application of HLAMatchmaker to the analysis of anti-
body reactivity may increase our understanding of otherwise
unexplained sensitization patterns induced by a given mismatch.
For instance, sensitization to certain HLA-C mismatches can
lead to antibodies reacting with epitopes shared with HLA-B
antigens (Lomago et al., 2010; Duquesnoy and Marrari, 2011).
These ﬁndings demonstrate that sensitization induced by an epi-
tope on a HLA-C mismatch may cause other class I antigens to
become unacceptable mismatches because they share that epi-
tope although the patient may have never been exposed to such
antigens. HLAMatchmaker can also explain unexpected reactivity
patterns of class II antibodies. For instance, patients sensitized
by a DR2 mismatch have often antibodies reacting with DR1
(Marrari and Duquesnoy, 2009). Such antibodies are induced by
DR51 which is in strong linkage disequilibrium with DR2. They
are speciﬁc for the 96EV eplet shared between DR51 and DR1.
Conversely,sensitization by a DR1 mismatch can lead to antibod-
ies that react also with DR51 but not with DR2. These ﬁndings
demonstrate the importance of DRB3/4/5 eplets in DRB-speciﬁc
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antibody responses of kidney transplant recipients (Duquesnoy
et al.,2008b).
HLA-DQ and HLA-DP heterodimers have distinct eplet reper-
toires and certain DQ and DP eplets react often with class II
antibodies(Duquesnoy,2008b;Duquesnoyetal.,2008b).DQanti-
bodies can also recognize pairs of eplets shared between DQA and
DQB chains (Tambur et al.,2010).
HLA MISMATCH ACCEPTABILITY FOR SENSITIZED PATIENTS
In the clinical setting of transplantation, it has become apparent
that HLA epitopes rather than antigens are important for analyz-
ing antibody speciﬁcity. The highly sensitized patient represents
an enigma for kidney transplantation: not only is it difﬁcult to
ﬁnd a suitably matched donor but subsequent kidney transplants
are often less successful. The analysis of serum reactivity for HLA
antibodies has two goals. Most commonly used is the identiﬁca-
tion of antibody-deﬁned HLA antigens that should be considered
unacceptable.Thissystemisdesignedtoidentifydonorswhomust
be excluded but it does not necessarily mean that all other HLA
antigens would be compatible for a patient. The other goal is
to determine HLA antigens that are acceptable mismatches. This
strategyrepresentsadirectapproachofﬁndingacompatibledonor
for a sensitized patient (Claas et al.,1989,2004).
HLAMatchmaker is a useful tool in the analysis of serum anti-
body reactivity of sensitized patients and the identiﬁcation of
potential donors with acceptable mismatches (Claas et al., 2004,
2005;Duquesnoyetal.,2004;Doxiadisetal.,2005;Goodmanetal.,
2006). Eurotransplant has incorporated HLAMatchmaker in the
AcceptableMismatchprogramtoidentifydonorsforhighlysensi-
tized patients (Claas et al., 2004, 2005; Doxiadis et al., 2005). This
approach shortens the waiting time for a suitable kidney donor
and leads to excellent graft survivals comparable to those seen
with non-sensitized recipients (Claas et al.,2004).
HLA IMMUNOGENICITY AND EPITOPE LOAD
HLAMatchmaker can be used as a quantitative tool to determine
thedegreeof amismatch,i.e.,thenumberof mismatchedepletsor
triplets.AgivenHLAantigenmismatchhasanepitopeloadthatis
primarily determined by the recipient’s HLA type representing a
repertoireof self epitopestowhichnoalloantibodiescanbemade.
For some patients, a mismatched antigen might be structurally
compatible whereas for other patients it has multiple mismatched
epitopes (Duquesnoy, 2008a). Table 1 shows examples of eplet
mismatches of two class I alleles for eight HLA phenotypes. For
each allele, one can readily identify cases with low or high eplet
loads.
The incidence of the anti-class I antibody response induced
by a transplant or during pregnancy correlates with the number
of non-self triplets or eplets on mismatched antigens (Dankers
et al.,2004; Goodman et al.,2006; Mihaylova et al.,2006; Kosmo-
liaptsis et al., 2008). Anti-HLA-C antibody responses by patients
with rejected kidney transplants also correlate with eplet loads of
HLA-C mismatches (Duquesnoy and Marrari, 2011).
Conventional class II matching criteria consider only HLA-DR
antigen but this approach is an insufﬁcient reﬂection of class
II compatibility because antibodies against other class II mis-
matches including DP and DQ have been shown to diminish
transplantsuccess.EachDRantigenshouldbeviewedasapackage
of DR+DQ+DP antigens and the overall class II epitope load
depends on the patient’s DR, DQ, DP type. Table 2 illustrates
how DR haplotypes have different epitope loads if DRB3/4/5,
DQB, and DQA are included. Let as assume that DR11, 16
corresponds to DRB1∗11:01, DRB3∗02:01, DQB1∗03:01, DQA1∗
05:01/DRB1∗16:01, DRB5∗02:02, DQB1∗05:02, DQA1∗01:02
genotype, and that the serological DR antigens correspond to the
common DR–DQ haplotypes shown in Table 2. The DR12 and
DR15 mismatches have the lowest eplet loads namely 6 and 9,
whereas DR7 and DR9 have 28 and 27 mismatched eplets,respec-
tively. The donor’s DRB1∗16:02 has two eplet differences with the
recipient’sDRB1∗16:01.ThisDRB1∗15:01haplotypehasnoDRB1
eplet mismatches but its DRB5∗01:01 and DQB1∗06:02 have 2
and 7 mismatched eplets, respectively. These examples are merely
intended to illustrate that high-resolution DR, DQ typing can
provide detailed class II matching information at the eplet level.
Table 1 |Two examples showing how the HLA phenotype of the recipient affects the eplet load of a class I allele mismatch (Adapted from
Duquesnoy, 2008b).
Case Phenotype B51 (B*51:01) B61 (B*40:02)
#Ep Mismatched
eplets
#Ep Mismatched
eplets
1 A*01:01 A*02:01 B*14:02 B*07:02 C*07:01 C*07:02 7 11AMR, 44RTE, 76ERI,
82ALR, 113HN, 163L, 193PV
5 9H, 41T, 44RKE, 113HN,
151RV
2 A*01:01 A*02:01 B*07:02 B*08:01 C*07:01 C*07:02 6 44RTE, 76ERI, 82ALR, 131S,
163L, 193PV
3 9H, 41T, 44RKE
3 A*01:01 A*02:01 B*07:02 B*45:01 C*07:01 C*07:02 5 44RTE, 76ERI, 82ALR,
113HN, 193PV
1 113HN
4 A*01:01 A*25:01 B*07:02 B*08:01 C*07:01 C*07:02 4 44RTE, 131S, 163L, 193PV 3 9H, 41T, 44RKE
5 A*01:01 A*02:01 B*07:02 B*44:03 C*05:01 C*07:02 3 44RTE, 76ERI, 113HN 2 9H, 113HN
6 A*01:01 A*02:01 B*45:01 B*39:01 C*05:01 C*17:01 3 44RTE, 76ERI, 82ALR 0 None
7 A*01:01 A*25:01 B*55:01 B*37:01 C*06:02 C*07:02 2 116Y, 163L 4 41T, 44RKE, 116Y, 163E
8 A*01:01 A*25:01 B*35:01 B*41:01 C*06:02 C*04:01 0 None 1 163E
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Table 2 | Example showing how a high-resolution DR–DQ haplotype shows differences in class II eplet loads among serologically deﬁned DR
antigen mismatches (Adapted from Duquesnoy, 2008a).
RECIPIENT
DR11: DRB1*11:01 DRB3*02:01 DQB1*03:01 DQA1*05:01
DR16: DRB1*16:01 DRB5*02:02 DQB1*05:02 DQA1*01:02 Eplet DRB1 DRB3/4/5 DQB1 DQA1
Donor Total Eplets Eplets Eplets Eplets
DR1 DRB1*01:01 None DQB1*05:01 DQA1*01:01 12 8 0 2 2
DR4 DRB1*04:01 DRB4*01:01 DQB1*03:01 DQA1*03:02 16 3 8 0 5
DR7 DRB1*07:01 DRB4*01:01 DQB1*02:02 DQA1*02:01 28 7 8 7 6
DR8 DRB1*08:01 None DQB1*04:02 DQA1*04:01 12 4 0 5 3
DR9 DRB1*09:01 DRB4*01:01 DQB1*03:03 DQA1*03:02 27 11 8 3 5
DR10 DRB1*10:01 None DQB1*05:01 DQA1*01:01 12 8 0 2 2
DR11 DRB1*11:01 DRB3*02:02 DQB1*03:01 DQA1*05:01 0 0 0 0 0
DR12 DRB1*12:01 DRB3*02:02 DQB1*03:01 DQA1*05:01 6 6 0 0 0
DR13 DRB1*13:01 DRB3*01:01 DQB1*06:03 DQA1*01:03 20 3 7 8 2
DR14 DRB1*14:01 DRB3*02:02 DQB1*05:03 DQA1*01:04 13 8 0 2 3
DR15 DRB1*15:01 DRB5*01:01 DQB1*06:02 DQA1*01:02 9 0 2 7 0
DR16 DRB1*16:02 DRB3*02:02 DQB1*03:01 DQA1*05:01 2 2 0 0 0
DR17 DRB1*03:01 DRB3*01:01 DQB1*02:01 DQA1*05:01 19 5 7 7 0
DR18 DRB1*03:02 DRB3*01:01 DQB1*04:02 DQA1*04:01 18 3 7 5 3
Epitope loads of class II mismatches affect speciﬁc antibody
responses.Donor-speciﬁc,DRB1-reactiveantibodiesarelessoften
detectablethanantibodiesagainstotherclassIIepitopes(Duques-
noy et al., 2008b). Antibody absence correlates with low numbers
of mismatchedDRB1eplets.Incontrast,donor-speciﬁcDRB3/4/5
mismatchesinducemoreantibodyresponsesandtheyhavehigher
numbers of incompatible eplets. Anti-DQ antibodies are rather
commonandthiscorrelateswithmoremismatchedepletsonDQB
and DQA than on DRB1 (Duquesnoy et al., 2008b). About one-
thirdofclassIIsensitizedpatientshaveanti-DPantibodiesreactive
with a few DPB eplets and an allelic pair of DPA eplets.
Information about epitope loads of HLA mismatches seems
clinically useful in the management of transplant patients. Epi-
topeloadscanbeinterpretedasriskfactorsforantibody-mediated
rejection in the clinical management of transplant recipients and
may eventually lead to new strategies for HLA mismatch per-
missibility to reduce alloimmunization and increase transplant
survival.
THE NON-SELF–SELF PARADIGM OF HLA EPLET
IMMUNOGENICITY
Our studies on eplet pairs have always shown that the immuniz-
ing allele has one eplet that is non-self whereas as the other is a
self eplet shared with the antibody producer (Duquesnoy et al.,
2005; Marrari et al., 2010). This suggests an autoreactive com-
ponent of the alloantibody response to an HLA mismatch and a
recentreporthasexpandedthisviewtothenon-self–selfparadigm
of eplet immunogenicity (Duquesnoy, 2011b). This paradigm is
based on current concepts about epitope–antibody interactions
and the development of B-cells speciﬁc for autologous proteins.
The variable domains of immunoglobulin heavy and light
chains determine antibody reactivity and each chain has three
complementaritydeterminingregions(CDRs)withhypervariable
loops that interact with different parts of an epitope (Poljak et al.,
1973; Chothia and Lesk,1987). The third CDR of the heavy chain
(CDR-H3) lies generally in the center of the antigen–binding site
and plays a major role in epitope recognition. CDR-H3 has con-
siderable variability in its length (Kabat et al., 1977; Wu et al.,
1993; MacCallum et al., 1996; Shirai et al., 1999) whereas the
other CDRs form limited numbers of so-called canonical struc-
tures that stabilize the binding with CDR-H3 (Chothia and Lesk,
1987; Kuroda et al., 2009). Stereochemical analyses of crystallized
antigen–antibody complexes have deﬁned a structural epitope as
that part of the antigen that makes contact with all CDRs of anti-
body (Davies et al., 1990; Padlan, 1994; MacCallum et al., 1996).
A structural epitope has about 15–25 surface residues and within
it lies the functional epitope consisting of energetic residues that
dominatethebindingwithantibody(Getzoffetal.,1988;Novotny,
1991; Laune et al., 1997;Van Regenmortel, 2002). Functional epi-
topescompriseonepatchorapairof patchesof energeticresidues
separated far enough to be contacted by different CDRs of anti-
body.Inordertobeimmunogenic,afunctionalepitopemusthave
at least one non-self residue, i.e., the antibody producer’s homol-
ogous proteins must have a different residue in the corresponding
sequenceposition.Suchresiduesmustbeonthemolecularsurface
sotheycanmakecontactwiththespeciﬁcity-determiningCDRsof
antibody. The surface of a structural epitope is about 700–900Å2
(Davies et al.,1990; Padlan,1994; MacCallum et al., 1996).
There is no information about the structure of an HLA anti-
gencomplexedwithalloantibodybutZiegler’sgrouphasobtained
detailed information about a crystallized antigen–antibody com-
plex involving a melanoma-associated peptide bound to HLA-A1
(Hulsmeyer et al., 2005). The structural epitope involves four
contact residues of the peptide and 10 contact residues in the
α helices of HLA-A1. These contact residues are on a molecu-
lar surface of about 900Å2. What are the possible dimensions
of structural HLA alloepitopes which have mismatched eplets
as functional epitopes? Considering the 700–900-Å2 surface of
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Table 3 | Examples of polymorphic residue differences within 15Å of mismatched eplets on antibody-deﬁned epitopes on immunizing alleles
and the alleles of the antibody producer.
Reference Antibody case Immunizing allele Epitope Numbers of residue differences for HLA alleles of antibody producer
25 Monoclonal 1 A*32:01 65RNA+S82LR A*02:01 A*24:02 B*07:02 B*40:01 C*07:02 C*03:04
627678
25 Monoclonal 2 B*27:05 163EW+S73TE A*01:01 B*08:01 C*07:01
10 2 6
25 Monoclonal 3 B*35:01 163LW+S65RQI A*02:01 A*24:02 B*07:02 B*40:01 C*07:02
98306
25 Monoclonal 4 A*ll:01 144KR+S151H A*02:01 A*25:01 B*18:01 B*51:01 C*12:03 C*15:02
166854
25 Monoclonal 5 B*55:01 65QIA+S76ES A*02:01 A*25:01 B*18:01 B*51:01 C*12:03 C*15:02
660422
25 Monoclonal 6 A*03:01 142MI+S79GT A*02:01 A*68:01 B*07:02 B*27:05 C*02:02 C*07:02
115745
41 Patient 1 B*44:02 S145R+S82LR A*30:01 A*66:01 B*13:02 B*14:02 C*06:02 C*08:02
790476
41 Patient 2 B*44:02 S145R+S82LR A*02:01 A*ll:01 B*07:02 B*13:02 C*06:02 C*07:02
1 0 95077
42 Monoclonal 7 B*44:03 41T A*01:01 A*25:01 B*08:01 B*18:01 C*07:01
75003
42 Monoclonal 8 B*07:02 80NRG A*02:01 A*24:02 B*27:05 B*37:01 C*02:02 C*06:02
1 0 60235
42 Monoclonal 9 B*15:03 163 LW A*02:01 A*68:01 B*07:02 B*27:05 C*02:02 C*07:02
642011
42 Monoclonal 10 B*55:01 69AA+S76E A*02:01 A*25:01 B*18:01 B*51:01 C*12:02
77033
42 Monoclonal 11 B*07:02 69AA A*25:01 A*29:02 B*15:01 B*44:02 C*05:01
77133
42 Monoclonal 12 B*49:01 80ERILR A*01:01 A*26:01 B*08:01 B*27:05 C*01:02 C*07:02
980235
a structural epitope one can calculate that surface residues within
a 15-Å radius of a centrally located eplet could make contact with
antibody. These residues can be identiﬁed with the“select by dis-
tance”commandoftheCn3Dstructuresoftwareprogram(Hogue,
1997)usinginformativeHLAmolecularmodelsdownloadedfrom
http://www.ncbi.nlm.nih.gov/Structure.
The non-self–self paradigm of eplet immunogenicity consid-
ers the hypothesis that B-cells carry low-afﬁnity immunoglobulin
receptors for self-HLA epitopes (Duquesnoy,2011b). Their inter-
actionswithself-HLAwillnotleadtoB-cellactivationorantibody
production. In contrast, exposure to HLA mismatches induces
often strong alloantibody responses. It seems that the activation
of a self-HLA speciﬁc B-cell by a non-self eplet requires that the
remainder of the structural epitope on the immunizing antigen
has considerable structural similarity with the corresponding self-
HLAepitopeof theantibodyproducer.Toassessthevalidityof the
non-self–self paradigm,we have determined polymorphic residue
differences within a 15-Å radius of an eplet on the immunizer
and the alleles of the antibody producer. The goal is to identify
the antibody producer’s structural epitope that has an identical or
very similar residue composition as the immunizing epitope with
the mismatched eplet.
Table 3 summarizes data in three recent publications as exper-
imental support of this hypothesis (Duquesnoy, 2011b; Marrari
et al., 2011; Duquesnoy et al., submitted). For each antibody
response, at least one allele of the antibody producer has no or
few differences with the immunizing allele in antibody-accessible
positions deﬁned by a 15-Å radius of the mismatched eplet, the
presumed dimension of a structural epitope. Most of the data
were obtained with human monoclonal antibodies (produced by
Arend Mulder, Leiden University Medical Center) that were spe-
ciﬁc for eplets or eplet pairs. In each case, the antibody producer
had at least one allele which had no or very residue differences
with the immunizing allele; they are highlighted in Table 3.T w o
patientshadantibodiesagainstthe145R+82LRpairpresentedby
theimmunizingB∗44:02;thisallelehasnoresiduedifferenceswith
the self B∗13:02 allele except for 145L rather than 145R. It should
be noted that both eplets are present on one or more alleles of the
antibody producer and, according to HLAMatchmaker, they are
considered intralocus and interlocus matches which should not
induce antibodies. None of the alleles of these antibody producers
had however, the combination of these eplets and the non-self–
self paradigm for HLA epitope immunogenicity has offered a
ready explanation why the pair of self-145R and self-82LR eplets
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presentedbyB∗44:02hadinducedspeciﬁcantibodies.TheB∗15:01
induced monoclonal 12 is also speciﬁc for a pair of self eplets,
namely s69TNT+s80NRG (Table 3). Within the 15-Å radius of
thispair,theB∗07:02alleleoftheantibodyproducerhadnoresidue
differences with B∗15:01.
These ﬁndings support the concept that HLA antibodies
originate from B-cells with self-HLA Immunoglobulin recep-
tors that recognize mismatched eplets as non-self entities on
immunizing antigens. The humoral alloresponse to an HLA
mismatch is not well understood. It is well known that sensi-
tized patients develop speciﬁc antibodies to a restricted number
of mismatched epitopes (Duquesnoy et al., 1990; Rodey et al.,
1994). The non-self–self paradigm of HLA epitope immuno-
genicity may explain this phenomenon. It is possible that the
antibody response to an eplet requires that its structural epi-
tope on the immunizing HLA antigen must be structurally very
similar to the corresponding self epitope of the antibody pro-
ducer. Any antigen with signiﬁcant structural epitope differ-
ences with patient’s self epitopes might prevent B-cell activation
and subsequent HLA antibody production. The non-self–self
concept of HLA immunogenicity may become clinically use-
ful regarding predicting antibody responses to HLA mismatches
but it needs of course, experimental veriﬁcation in the clinical
setting.
CONCLUSION
Prevention of HLA sensitization represents a signiﬁcant challenge
for the non-sensitized transplant candidate. Two causes, namely
blood transfusions and the transplant itself should be approached
as being potentially preventable. Perfect HLA matching is some-
what impractical because it can be done for small numbers of
patients. On the other hand,information about epitope loads and
theapplicationof thenon-self–self paradigmof epitopeimmuno-
genicity may useful in assessing risks for antibody-mediated
rejection after transplantation and the clinical management of
transplant recipients. Such permissible mismatching may lead to
new strategies to identify suitable donors with minimal risks for
allosensitization.
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